arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

BICYCLE THERAPEUTICS PLC

BCYC
$4.17 ▲ +0.20 (+5.04%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
36 Visible periods
33 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

BICYCLE THERAPEUTICS PLC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $291.1M
Dividend Yield
Revenue Growth -78.5%
Op. Margin None
ROIC -10.7%
FCF / Share $-0.71
Trailing P/E
Price / Book 0.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

36-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$629.00K
↓ -78.5%
Net Income Profit after all expenses
$-60.83M
— -0.1%
Operating Margin Operating profit as % of sales
-51.5%
↑ +89.7% 0th
FCF / Share Free cash flow per share
$-0.71
↑ +32.5%
Long-Term Debt Long-term obligations
$30.80M
↑ +0.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
21
Cash Quality
71

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 36 quarters